| Literature DB >> 29099418 |
Alfonso M Ferrara1, Giuseppe Lombardi2, Ardi Pambuku2, Domenico Meringolo3, Roberta Bertorelle4, Margherita Nardin5, Francesca Schiavi1, Maurizio Iacobone6, Giuseppe Opocher7, Vittorina Zagonel2, Stefania Zovato1.
Abstract
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors with a strong genetic background. The mainstay of treatment for PCC/PGLs is surgery. However, for unresectable lesions, no curative treatment is currently available. Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs. We report two cases of PCC/PGLs treated with TMZ. Case 1 is a 51-year-old man with local and distant recurrence (liver and bone metastases) of right adrenal PCC. Case 2 is a 54-year-old woman with a PCC/PGL syndrome caused by a mutation in MAX gene (c.171+1G>A), operated on for bilateral adrenal PCC and presenting with a large unresectable abdominal PGL. Both patients presented hypertension due to catecholamine hypersecretion. TMZ determined radiological response according to RECIST criteria, reduction of urinary catecholamine levels, and controlled hypertension in both patients. Furthermore, the current study demonstrates, for the first time, that MAX-related PGLs are responsive to TMZ.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29099418 DOI: 10.1097/CAD.0000000000000570
Source DB: PubMed Journal: Anticancer Drugs ISSN: 0959-4973 Impact factor: 2.248